Pharmaceuticals

Global Oncology Adjuvants Market 2026–2035 benefiting from increasing cancer treatment adoption

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Oncology Adjuvants Market Projected To Become By 2030 Based On Its 2026 Valuation?

The oncology adjuvants market has experienced robust expansion over recent years. Projections indicate it will expand from $1.73 billion in 2025 to $1.87 billion by 2026, achieving a compound annual growth rate (CAGR) of 8.2%. This historical growth is attributable to factors such as the restricted availability of oncology adjuvants, the continued dependence on chemotherapy and radiation as main treatments, the rising global prevalence of cancer, an uptick in clinical investigations into adjuvant therapies, and enhanced recognition of adjuvant advantages among oncologists.

The oncology adjuvants market size is expected to undergo significant growth in the coming years. It is projected to expand to $2.54 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.9%. The anticipated growth during this forecast period stems from the advancement of novel immunotherapy adjuvants, the increasing availability of targeted therapy options, a greater embrace of combination therapy approaches, the integration of precision medicine and genomic profiling, and a surge in investment in oncology research and clinical trials. Prominent trends for the forecast period include a rising adoption of immunotherapy and targeted therapy adjuvants, a stronger integration of personalized cancer treatment plans, the expansion of oral and subcutaneous administration pathways, growth in multi-modal cancer treatment strategies, and a focus on improving patient outcomes while reducing therapy side effects.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27370&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Oncology Adjuvants Market?

The future expansion of the oncology adjuvants market is anticipated to be driven by the growing need for personalized medicine. Personalized medicine is defined as a healthcare approach leveraging an individual’s genetic and lifestyle data to customize treatments and medical care to their unique requirements. Its increasing adoption stems from progress in genetic and molecular profiling, allowing therapies to be specifically designed for a patient’s distinct biological profile, thereby enhancing efficacy and minimizing side effects. Oncology adjuvants support personalized medicine by enabling the tailoring of supplementary cancer treatments according to a patient’s individual genetic composition and tumor features, thus ensuring therapies precisely target remaining cancer cells and reduce unwarranted adverse reactions. As an illustration, in February 2024, data from the US-based Personalized Medicine Coalition (PMC) indicated that in 2023, the FDA sanctioned 16 novel personalized treatments for rare disease patients, an increase from 6 in 2022. Consequently, the heightened demand for personalized medicine is fueling the expansion of the oncology adjuvants market.

What Segment Groups Are Identified Within The Oncology Adjuvants Market?

The oncology adjuvants market covered in this report is segmented –

1) By Type Of Adjuvant: Chemotherapy Adjuvants, Radiation Adjuvants, Immunotherapy Adjuvants, Hormonal Adjuvants, Targeted Therapy Adjuvants

2) By Administration Route: Oral, Intravenous, Subcutaneous, Topical, Intramuscular

3) By Indication: Breast Cancer, Glioblastoma, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Sarcoma, Prostate Cancer, Other Indications

4) By End User: Cancer Research Institute, Cancer Hospitals

Subsegments:

1) By Chemotherapy Adjuvants: Alkylating Agents, Antimetabolites, Anthracyclines, Plant Alkaloids, Topoisomerase Inhibitors, Platinum-Based Compounds, Others

2) By Radiation Adjuvants: Radiosensitizers, Radioprotectors, Hypoxic Cell Sensitizers, Deoxyribonucleic Acid (DNA) Repair Inhibitors, Immune Modulating Agents Combined With Radiation

3) By Immunotherapy Adjuvants: Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Adoptive Cell Transfer, Immune Modulating Agents

4) By Hormonal Adjuvants: Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Gonadotropin-Releasing Hormone Agonists Or Antagonists, Androgen Receptor Inhibitors, Estrogen Receptor Downregulators

5) By Targeted Therapy Adjuvants: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, mTOR Inhibitors, v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) Or Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors, Vascular Endothelial Growth Factor (VEGF) Inhibitors

What Trends Are Advancing Progress In The Oncology Adjuvants Market?

Leading companies within the oncology adjuvants market are actively pursuing the development of sophisticated solutions, including immune checkpoint inhibitor adjuvant therapy. This innovative approach seeks to enhance the effectiveness of post-surgical treatment and improve patient outcomes by harnessing the body’s natural immune defenses to target any remaining tumor cells. Immune checkpoint inhibitor adjuvant therapy utilizes medications that block immune checkpoint proteins such as PD-1, PD-L1, or CTLA-4, which normally suppress the immune system. A notable instance occurred in January 2023 when Merck & Co., Inc., a US-based pharmaceutical firm, launched KEYTRUDA (pembrolizumab). This treatment received Food and Drug Administration (FDA) approval as an adjuvant following surgical resection and platinum-based chemotherapy for individuals with Stage IB (T2a =4 centimeters), II, or IIIA non-small cell lung cancer (NSCLC). KEYTRUDA (pembrolizumab) functions by specifically inhibiting the PD-1 receptor, thereby restoring the immune system’s ability to detect and combat cancer cells. It provides an effective adjuvant therapy choice for non-small cell lung cancer (NSCLC) patients post-surgery and chemotherapy, contributing to a reduced risk of cancer recurrence and improved overall survival. Moreover, KEYTRUDA facilitates personalized cancer treatment by leveraging the patient’s individual immune response, positioning it as a crucial instrument in contemporary immuno-oncology.

Which Companies Hold Significant Positions In The Oncology Adjuvants Market?

Major companies operating in the oncology adjuvants market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Amgen Inc., Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Ipsen S.A., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Croda International Plc, Dynavax Technologies Corporation, Agenus Inc., Elicio Therapeutics Inc.

Read the full oncology adjuvants market report here:

https://www.thebusinessresearchcompany.com/report/oncology-adjuvants-global-market-report

Which Regions Are Projected To Dominate The Oncology Adjuvants Market In The Coming Years?

North America was the largest region in the oncology adjuvants market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology adjuvants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncology Adjuvants Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27370&type=smp

Browse Through More Reports Similar to the Global Oncology Adjuvants Market 2026, By The Business Research Company

Concrete Repair Mortars Market Report 2026

https://www.thebusinessresearchcompany.com/report/concrete-repair-mortars-global-market-report

Cumene Market Report 2026

https://www.thebusinessresearchcompany.com/report/cumene-global-market-report

Supplementary Cementitious Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/supplementary-cementitious-materials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795